Leaders in Medical Device Preclinical Research Join Forces as Surpass Acquires LyChron
January 17, 2017
Surpass and Surpass-Silicon Valley, LLC (formerly LyChron, LLC) to offer premier preclinical research services, accelerating progress along the product development pipeline.
Osceola, WI - Surpass, Inc. ("Surpass") announced today the acquisition of LyChron, LLC ("LyChron"), expanding its capacity to serve the medical device and preclinical research community. The new California entity will operate as Surpass-Silicon Valley, LLC.
Liann Johnson, President & CEO of Surpass, expressed her confidence in bringing the two companies together. "Given significant synergies in the core competencies of each organization, we now have the opportunity to identify best practices and implement them across the standard operating procedures to assure that our clients receive the highest quality preclinical study experience available today."
The operating environment for Contract Research Organizations has become increasingly challenging. Johnson continued, "Globally we are facing a strained economic landscape, and our clients, medical device and biopharmaceutical companies, are dealing with regulatory uncertainties and profit erosion." As a result of the acquisition, Surpass' and LyChron's clients will benefit by leveraging the combined resources, capacity and expertise of the organizations from the earliest feasibility/proof-of-concept to pivotal GLP-compliant studies.
LyChron was founded in 2000 by a team of scientists and physicians and provides proof-of-concept, feasibility, prototype evaluation, validation, and GLP safety preclinical studies, as well as facilitating physician and clinical training, refining study designs, and developing novel disease models. Located in Mountain View, CA, LyChron is experienced with the evaluation of medical devices, gene or cell therapies, and pharmacological agents intended for human and veterinary clinical trials and ultimate market release.